Maze Therapeutics

Recent news

• Company notice
  Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sohn Catherine A.
  SEC · 2025/9/25
• Wedbush Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $48
  Market Newswire · 2026/9/23
• Rating change
  Analysts Are Bullish on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Mirum Pharmaceuticals (MIRM)
  TipRanks · 2026/9/10
• Company notice
  Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Sohn Catherine A.
  SEC · 2026/1/9
• Rating change
  Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $64
  Market Newswire · 2026/8/14
• H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110
  Market Newswire · 2026/10/5
• Rating change
  Wells Fargo Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $55
  Market Newswire · 2026/9/10
• Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX) and Aytu BioScience (AYTU)
  TipRanks · 2026/9/23
• Company notice
  Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Third Rock Ventures IV, L.P.
  SEC · 2025/11/6
• Rating change
  Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)
  TipRanks · 2026/8/12
• Company notice
  Maze Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Third Rock Ventures IV, L.P.
  SEC · 2025/2/4
• Rating change
  A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $48 to $110
  Market Newswire · 2026/8/13
• Citi Initiates Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $50
  Market Newswire · 2026/9/24
• Rating change
  Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)
  TipRanks · 2026/8/12
• Rating change
  Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE) and Ionis Pharmaceuticals (IONS)
  TipRanks · 2026/9/23
• Rating change
  Analysts Are Bullish on Top Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX)
  TipRanks · 2026/9/23
• Rating change
  Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE)
  TipRanks · 2026/9/22
• Rating change
  A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $46 to $110
  Market Newswire · 2026/9/23
• Company notice
  GiXo: Gix Makes Maze Co., Ltd. a Subsidiary - Strengthening the System to Promote the Data Infrastructure Utilization Service “CU/ADS (Quads)”
  JPX · 2025/10/2
• HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price Target
  Benzinga · 2026/9/24

Headlines are aggregated automatically and are not independently verified or edited by our team.